Alberta Is Second Canadian Province To Switch To Biosimilars
Follows British Columbia Switching Program That Began This Year
Executive Summary
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
You may also be interested in...
Alberta Expands Biosimilar Switching With Adalimumab
Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.
Third Canadian Province Follows On Biosimilar Switching
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
Canadian Biosimilars Body Calls For Expansion Of Switching
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.